Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus PRADAXA.
LIQUAEMIN LOCK FLUSH vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category C
Category C
Anticoagulant
Anticoagulant